Alvotech is lined up to copy 6 of the blockbuster drugs on this tracker, which earned $31.3B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Alvotech's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Stelara Selarsdi |
Johnson & Johnson | Biosimilar | 2025 | FDA-approved biosimilar | $6.1B |
| Entyvio AVT16 |
Takeda | Biosimilar | 2032 | Under FDA review; decision expected Q1 2027 | ≈$6.0B |
| Taltz AVT28 |
Eli Lilly | Biosimilar | 2030 | Early development | $3.6B |
| Tremfya | Johnson & Johnson | Biosimilar | 2031 | Early development | $5.2B |
| Kesimpta | Novartis | Biosimilar | 2031 | Early development (Europe partner: Advanz) | $4.4B |
| Imfinzi AVT34 |
AstraZeneca | Biosimilar | 2031 | Early development | $6.1B |
Company facts: SEC company tickers. Each drug page lists sources for these entries. Brand sales show the size of the market, not Alvotech's share of it.